Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2

被引：21
|
作者：
Mveang Nzoghe, Amandine [1 ]
Essone, Paulin N. [2 ,3 ,4 ]
Leboueny, Marielle [1 ]
Maloupazoa Siawaya, Anicet Christel [1 ]
Bongho, Eliode Cyrien [1 ]
Mvoundza Ndjindji, Ofilia [1 ]
Avome Houechenou, Rotimi Myrabelle [1 ]
Agnandji, Selidji Todagbe [2 ,3 ,4 ]
Djoba Siawaya, Joel Fleury [1 ]
机构：
[1] Fdn Jeanne EBORI, CHU Mere Enfant, Serv Lab, Unite Rech & Diagnost Specialise, BP212, Libreville, Gabon
[2] Ctr Recherches Med Lambarene, Lambarene, Gabon
[3] Univ Tubingen, Inst Trop Med, Tubingen, Germany
[4] Univ Tubingen, German Ctr Infect Res, Tubingen, Germany
来源：
IMMUNITY INFLAMMATION AND DISEASE | 2021年 / 9卷 / 01期
关键词：
D O I：
10.1002/iid3.367
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim: We aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2. Method: We have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay. Results: Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies. Conclusion: Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
引用
收藏
页码：128 / 133
页数：6
相关论文
共 50 条
  • [21] Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam
    Nguyen, Thi Thanh Ngan
    Choo, Ee Mei
    Nakamura, Yukio
    Suzuki, Ryuji
    Shiina, Takashi
    Shin-I, Tadasu
    Fukuta, Mizuki
    Nguyen, Co Thach
    Nguyen, Thi Thu Thuy
    Nguyen, Le Khanh Hang
    Hoang, Vu Mai Phuong
    Morita, Kouichi
    Dang, Duc Anh
    Hasebe, Futoshi
    Le, Thi Quynh Mai
    Moi, Meng Ling
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 139 : 109 - 117
  • [22] Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
    Hauser, Blake M.
    Sangesland, Maya
    Lam, Evan C.
    Feldman, Jared
    Balazs, Alejandro B.
    Lingwood, Daniel
    Schmidt, Aaron G.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
    Souris, Marc
    Tshilolo, Leon
    Parzy, Daniel
    Ingoba, Line Lobaloba
    Ntoumi, Francine
    Kamgaing, Rachel
    Ndour, Moussa
    Mbongi, Destin
    Phoba, Balthazar
    Tshilolo, Marie-Anasthasie
    Mbungu, Rene
    Sosso, Martin Samuel
    Fainguem, Nadine
    Dieye, Tandakha Ndiaye
    Sylla, Massamba
    Morand, Pierre
    Gonzalez, Jean-Paul
    VIRUSES-BASEL, 2022, 14 (10):
  • [24] Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells
    Fernando Garcia-Jimenez, Alvaro
    Caceres-Martell, Yaiza
    Fernandez-Soto, Daniel
    Martinez Fleta, Pedro
    Casasnovas, Jose M.
    Sanchez-Madrid, Francisco
    Rodriguez Frade, Jose Miguel
    Vales-Gomez, Mar
    Reyburn, Hugh T.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2022, 112 (02) : 339 - 346
  • [25] SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
    Tang, Weiyi
    Chang, Zi Wei
    Goh, Yun Shan
    Tan, Yong Jie
    Hor, Pei Xiang
    Loh, Chiew Yee
    Lye, David C.
    Young, Barnaby E.
    Ng, Lisa F. P.
    Tay, Matthew Zirui
    Renia, Laurent
    VACCINES, 2025, 13 (03)
  • [26] Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
    Reche, Pedro A.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [27] Pre-Existing Microbiome Signature in a SARS-CoV-2 Discordant Family
    Hazan, Sabine
    CASE REPORTS IN GASTROENTEROLOGY, 2022, 16 (01) : 15 - 22
  • [28] Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
    Lee, Eun-Ju
    Beltrami-Moreira, Marina
    Al-Samkari, Hanny
    Cuker, Adam
    DiRaimo, Jennifer
    Gernsheimer, Terry
    Kruse, Alexandra
    Kessler, Craig
    Kruse, Caroline
    Leavitt, Andrew D.
    Lee, Alfred I.
    Liebman, Howard A.
    Newland, Adrian C.
    Ray, Ashley E.
    Tarantino, Michael D.
    Thachil, Jecko
    Kuter, David J.
    Cines, Douglas B.
    Bussel, James B.
    BLOOD, 2021, 138
  • [29] SARS-CoV-2 and Pre-existing Vascular Diseases: Guilt by Association?
    Voulalas, Grigorios
    Tsui, Janice
    Candilio, Luciano
    Baker, Daryll
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2021, 15
  • [30] Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
    Abela, Irene A.
    Pasin, Chloe
    Schwarzmueller, Magdalena
    Epp, Selina
    Sickmann, Michele E.
    Schanz, Merle M.
    Rusert, Peter
    Weber, Jacqueline
    Schmutz, Stefan
    Audige, Annette
    Maliqi, Liridona
    Hunziker, Annika
    Hesselman, Maria C.
    Niklaus, Cyrille R.
    Gottschalk, Jochen
    Schindler, Emery
    Wepf, Alexander
    Karrer, Urs
    Wolfensberger, Aline
    Rampini, Silvana K.
    Sauteur, Patrick M. Meyer
    Berger, Christoph
    Huber, Michael
    Boeni, Juerg
    Braun, Dominique L.
    Marconato, Maddalena
    Manz, Markus G.
    Frey, Beat M.
    Guenthard, Huldrych F.
    Kouyos, Roger D.
    Trkola, Alexandra
    NATURE COMMUNICATIONS, 2021, 12 (01)
12345